These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Tumor necrosis factor inhibitors in psoriasis: an update.
    Author: Kerdel FA, Strober BE.
    Journal: Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543.
    Abstract:
    Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.
    [Abstract] [Full Text] [Related] [New Search]